Auriga Laboratories Announces The Launch Of Extendryl(R) PEM And Extendryl(R) GCP

Main Category: Flu / Cold / SARS
Also Included In: Allergy
Article Date: 24 Mar 2008 - 11:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the launch of Extendryl® PEM and Extendryl® GCP. The two new products will be marketed under the Extendryl brand name which consists of prescription products to treat various cough, cold, and allergy symptoms.

The prescription respiratory market is valued at more than 8 billion dollars in sales and more than 68 million prescriptions are written annually in the US. Extendryl® PEM (phenylephrine HCl 30 mg; methscopolamine nitrate 1.25 mg) Tablets combine two compounds; a decongestant with an anticholinergic/drying agent in an extended release format to provide 8 to 12 hours of relief of symptoms for adults suffering from nasal congestion and mucosal drainage associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis, and asthma. Extendryl® GCP Oral Solution combines three compounds (100 mg/5 mL guaifenesin; 15 mg/5mL carbetapentane citrate; 5 mg/mL hydrochloride), and is indicated for temporary relief of non-productive cough accompanying respiratory tract congestion associated with the common cold, influenza, sinusitis, and bronchitis.

Extendryl® PEM and Extendryl®GCP will be launched in March 2008. "These new products further solidify Auriga's commitment to enhance the Extendryl product line, and the launch is well timed to coincide with the start of Spring allergy season. These new additions to the Extendryl family will be a highly synergistic addition to Auriga's current promotional efforts," said Frank Greico, Chief Executive Officer of Auriga.

Extendryl is contraindicated in patients who are sensitive to any of the ingredients or related compounds, and in patients with glaucoma, hypertension, cardiac disease, hyperthyroidism, urinary retention, peptic ulcer, patients on MAO inhibitor therapy and during an asthmatic attack. Extendryl GCP is contraindicated in women who are pregnant and/or nursing. Extendryl PEM is contraindicated in children under 6 years of age. See individual product package inserts for full prescribing information.

About Auriga Laboratories™

Auriga Laboratories is a specialty pharmaceutical company building an extensive product portfolio of prescription brands targeting high growth therapeutic categories in the respiratory, dermatology, and psychiatry markets, which have combined annual revenues of more than fifteen billion dollars in the United States. The company's high-growth business model combines driving revenues through a primarily variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral™ for the treatment of Xerostomia, Akurza™, Xyralid™, Zytopic™, and Coraz™ dermatology products, and the Zinx™ Extendryl ®, and Levall ® Families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit http://www.aurigalabs.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity.

The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the development of additional products, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

Auriga Laboratories